BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7822879)

  • 1. Autoimmunity and antibodies to interferons in patients with carcinoid tumors--clinical consequences.
    Oberg KE
    J Interferon Res; 1994 Aug; 14(4):215-6. PubMed ID: 7822879
    [No Abstract]   [Full Text] [Related]  

  • 2. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.
    Rönnblom LE; Alm GV; Oberg KE
    Ann Intern Med; 1991 Aug; 115(3):178-83. PubMed ID: 2058872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of carcinoid syndrome with recombinant interferon alpha-2a.
    Di Bartolomeo M; Bajetta E; Zilembo N; de Braud F; Di Leo A; Verusio C; D'Aprile M; Scanni A; Barduagni M; Barduagni A [corrected to Barduagni M]
    Acta Oncol; 1993; 32(2):235-8. PubMed ID: 7686766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of tumor response to interferon in a malignant ECL cell carcinoid of the stomach.
    Franzé A; Muzzetto PA; De Lisi V; Bordi C
    Am J Gastroenterol; 1992 Jul; 87(7):931-2. PubMed ID: 1615961
    [No Abstract]   [Full Text] [Related]  

  • 5. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon.
    Kälkner KM; Rönnblom L; Karlsson Parra AK; Bengtsson M; Olsson Y; Oberg K
    QJM; 1998 Jun; 91(6):393-9. PubMed ID: 9709457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyrotoxicosis after interferon-alpha therapy.
    Csaki AC; Blum M
    Thyroid; 2000 Jan; 10(1):101. PubMed ID: 10691322
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K; Alm GV
    J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acute renal insufficiency secondary to interferon].
    Laboudi A; Makdassi R; Choukroun G; Fournier A
    Nephrologie; 2003; 24(4):181-5. PubMed ID: 12891833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon.
    Ahren B; Engman K; Lindblom A
    Anticancer Res; 1992; 12(1):129-33. PubMed ID: 1567158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and therapy monitoring of liver metastases from neuroendocrine tumours.
    Andersson T
    Acta Radiol Suppl; 1991; 375 ( Pt 2)():91-107. PubMed ID: 1726275
    [No Abstract]   [Full Text] [Related]  

  • 11. Interferons in the management of neuroendocrine tumors and their possible mechanism of action.
    Oberg K
    Yale J Biol Med; 1992; 65(5):519-29; discussion 531-6. PubMed ID: 1340065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia in patients with midgut carcinoid, treated with alpha interferon: effects by erythropoietin treatment on the perceived quality of life.
    Larsson G; Janson ET
    Eur J Cancer Care (Engl); 2008 Mar; 17(2):200-4. PubMed ID: 18302658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial.
    Janson ET; Kauppinen HL; Oberg K
    Acta Oncol; 1993; 32(2):231-3. PubMed ID: 8323762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
    Nilsson A; Janson ET; Eriksson B; Larsson A
    Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
    Kölby L; Persson G; Franzén S; Ahrén B
    Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha and autoimmune thyroid disease.
    Prummel MF; Laurberg P
    Thyroid; 2003 Jun; 13(6):547-51. PubMed ID: 12930598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.
    Janson ET; Oberg K
    Acta Oncol; 1993; 32(2):225-9. PubMed ID: 7686765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment with interferon and autoimmunity].
    Gaja A; Franková H; Kocák I; Slapnicková J; Hejlová N
    Vnitr Lek; 1999 Jul; 45(7):409-13. PubMed ID: 11045159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha and its contribution to autoimmunity.
    Selmi C; Lleo A; Zuin M; Podda M; Rossaro L; Gershwin ME
    Curr Opin Investig Drugs; 2006 May; 7(5):451-6. PubMed ID: 16729722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
    Chung YH; Shong YK
    Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.